Tissue Expression of the Proteins Fas and Fas Ligand in Colorectal Cancer and Liver Metastases

Overview

Journal J Gastrointest Cancer

Publisher Springer

Specialties Gastroenterology
Oncology

Date 2011 Jan 29

PMID 21271302

Citations 7

Authors

Stylianos Kykalos

Spuridon Mathaiou

Anastasios J Karayiannakis

Dimitris Patsouras

Maria Lambropoulou

Constantinos Simopoulos

Affiliations

Soon will be listed here.

Abstract

Background And Aim: Our purpose is to study the clinical significance of Fas/FasL expression in colon cancer and liver metastases (LM).

Material And Methods: The expression of Fas/FasL in 68 patients with colon cancer was examined immunohistochemically and correlated to the clinicopathological features of the tumors.

Results: High expression of FasL, was observed in stage D and in LM (p=0.024). Fas expression was reduced in stage D tumors and in LM, when compared to earlier stages of disease (p=0.024). LM had also shown a decreased expression of Fas (p=0.016). Tumors with low FasL expression upregulate more often their Fas expression (p = 0.028). No correlation could be established regarding the patients survival.

Conclusions: Low expression of Fas and high expression of FasL are more often in colon tumor stage D and in liver metastasis; these imply tumor aggression, resistance against apoptosis, and could be held as negative prognostic factors.

Citing Articles

Molecular Docking of Lactoferrin with Apoptosis-Related Proteins Insights into Its Anticancer Mechanism.

Angel-Lerma L, Carrillo-Campos J, Sianez-Estrada L, Siqueiros-Cendon T, Leon-Flores D, Espinoza-Sanchez E Int J Mol Sci. 2025; 26(5).

PMID: 40076649 PMC: 11899785. DOI: 10.3390/ijms26052023.

Suppression of PKCδ/NF-κB Signaling and Apoptosis Induction through Extrinsic/Intrinsic Pathways Are Associated Magnolol-Inhibited Tumor Progression in Colorectal Cancer In Vitro and In Vivo.

Su C, Weng Y, Kuan L, Chen J, Hsu F Int J Mol Sci. 2020; 21(10).

PMID: 32429376 PMC: 7278962. DOI: 10.3390/ijms21103527.

Apoptotic signalling targets the post-endocytic sorting machinery of the death receptor Fas/CD95.

Sharma S, Carmona A, Skowronek A, Yu F, Collins M, Naik S Nat Commun. 2019; 10(1):3105.

PMID: 31308371 PMC: 6629679. DOI: 10.1038/s41467-019-11025-y.

CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis.

Pothoulakis C, Torre-Rojas M, Duran-Padilla M, Gevorkian J, Zoras O, Chrysos E Int J Cancer. 2017; 142(2):334-346.

PMID: 28929494 PMC: 5918308. DOI: 10.1002/ijc.31064.

Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.

Cacan E, Spring A, Kumari A, Greer S, Garnett-Benson C Int J Mol Sci. 2015; 16(12):30405-21.

PMID: 26703577 PMC: 4691179. DOI: 10.3390/ijms161226238.

References

Korkolopoulou P, Saetta A, Levidou G, Gigelou F, Lazaris A, Thymara I . c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Histopathology. 2007; 51(2):150-6. DOI: 10.1111/j.1365-2559.2007.02723.x. View

Reed J, Hakam A, Nicosia S, Coppola D . Significance of Fas receptor protein expression in epithelial ovarian cancer. Hum Pathol. 2005; 36(9):971-6. DOI: 10.1016/j.humpath.2005.06.015. View

Lee W, Yu M, Chen M . Prognostic impact of Fas ligand on hepatocellular carcinoma after hepatectomy. World J Surg. 2004; 28(8):792-6. DOI: 10.1007/s00268-004-7254-2. View

Backus H, Van Groeningen C, Vos W, Dukers D, Bloemena E, Wouters D . Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases. J Clin Pathol. 2002; 55(3):206-11. PMC: 1769617. DOI: 10.1136/jcp.55.3.206. View

Sugita J, Ohtani H, Mizoi T, Saito K, Shiiba K, Sasaki I . Close association between Fas ligand (FasL; CD95L)-positive tumor-associated macrophages and apoptotic cancer cells along invasive margin of colorectal carcinoma: a proposal on tumor-host interactions. Jpn J Cancer Res. 2002; 93(3):320-8. PMC: 5926973. DOI: 10.1111/j.1349-7006.2002.tb02175.x. View

OConnell J, Bennett M, OSullivan G, Collins J, Shanahan F . Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack. Dis Esophagus. 1999; 12(2):83-9. DOI: 10.1046/j.1442-2050.1999.00033.x. View

Nijhawan D, Honarpour N, Wang X . Apoptosis in neural development and disease. Annu Rev Neurosci. 2000; 23:73-87. DOI: 10.1146/annurev.neuro.23.1.73. View

Chopin D, Barei-Moniri R, Maille P, Le Frere-Belda M, Muscatelli-Groux B, Merendino N . Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol. 2003; 162(4):1139-49. PMC: 1851234. DOI: 10.1016/S0002-9440(10)63910-7. View

Bennett M, OConnell J, Houston A, Kelly J, OSullivan G, Collins J . Fas ligand upregulation is an early event in colonic carcinogenesis. J Clin Pathol. 2001; 54(8):598-604. PMC: 1731496. DOI: 10.1136/jcp.54.8.598. View

10.

Belluco C, Esposito G, Bertorelle R, Alaggio R, Giacomelli L, Bianchi L . Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence. Eur J Surg Oncol. 2002; 28(2):120-5. DOI: 10.1053/ejso.2001.1223. View

11.

Kramer G, Erdal H, Mertens H, Nap M, Mauermann J, Steiner G . Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res. 2004; 64(5):1751-6. DOI: 10.1158/0008-5472.can-03-2455. View

12.

Liu Z, Liu R, Qiu J, Yin P, Luo F, Su J . Combination of human Fas (CD95/Apo-1) ligand with adriamycin significantly enhances the efficacy of antitumor response. Cell Mol Immunol. 2009; 6(3):167-74. PMC: 4003059. DOI: 10.1038/cmi.2009.23. View

13.

Ohno S, Tachibana M, Shibakita M, Dhar D, Yoshimura H, Kinugasa S . Prognostic significance of Fas and Fas ligand system-associated apoptosis in gastric cancer. Ann Surg Oncol. 2000; 7(10):750-7. DOI: 10.1007/s10434-000-0750-1. View

14.

Lambert C, Landau A, Desbarats J . Fas-beyond death: a regenerative role for Fas in the nervous system. Apoptosis. 2003; 8(6):551-62. DOI: 10.1023/A:1026113222478. View

15.

Koomagi R, Volm M . Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer. 1999; 84(3):239-43. DOI: 10.1002/(sici)1097-0215(19990621)84:3<239::aid-ijc7>3.0.co;2-s. View

16.

Houston A, Michael-Robinson J, Walsh M, Cummings M, Ryan A, Lincoln D . The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability. Hum Pathol. 2007; 39(2):243-50. DOI: 10.1016/j.humpath.2007.06.010. View

17.

Mann B, Gratchev A, Bohm C, Hanski M, Foss H, Demel G . FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer. 1999; 79(7-8):1262-9. PMC: 2362258. DOI: 10.1038/sj.bjc.6690202. View

18.

OConnell J, Bennett M, OSullivan G, OCallaghan J, Collins J, Shanahan F . Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immunol. 1999; 6(4):457-63. PMC: 95708. DOI: 10.1128/CDLI.6.4.457-463.1999. View

19.

Koornstra J, de Jong S, Hollema H, de Vries E, Kleibeuker J . Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. Crit Rev Oncol Hematol. 2002; 45(1):37-53. DOI: 10.1016/s1040-8428(01)00228-1. View

20.

Bernstorff W, Glickman J, Odze R, Farraye F, Joo H, Goedegebuure P . Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer. 2002; 94(10):2552-60. DOI: 10.1002/cncr.10549. View